GC Biopharma Corp

GC Biopharma is a South Korean biopharmaceutical business based in Yongin. GC Pharma focuses in the discovery and marketing of oncology and infectious disease vaccines, protein treatments, and therapeutic antibodies. The company is involved in biotherapeutics research, development, manufacture, and sales, including plasma proteins, recombinant antibodies, and vaccines. Green Cross created "Hepavax B," the world's third hepatitis B vaccine, in 1983, "Hantavax," the world's first vaccine against epidemic hemorrhagic fever in 1988, the world's second varicella vaccine in 1995, "Greengene," the world's fourth recombinant antihemophilic drug, and "Hunterase," the world's second Hunter syndrome treatment, in 2012 as well as one of the largest pharma companies in South Korea.

GC Biopharma, a South Korean biotechnology pioneer, is gearing up to take another significant step toward guaranteeing a better and happier future for all people globally. The essential principles that govern GC Biopharma on its journey toward its next goal are challenge and innovation, care and compassion, transparency and honesty, and respect and dedication. Its mission is to usher in a brighter and healthier future for all of humanity. Over the last five decades, GC Biopharma has been involved in a wide range of pharmaceutical research and development.

Pharmaceutical research is fraught with difficulties and difficulties. Recognizing the importance of its mission to those suffering from sickness, GC Biopharma has been relentlessly pursuing its goal of being a global health sector leader. GC Biopharma is now poised to join the ranks of the global health industry as an active participant in the research, development, and delivery of a diverse range of pharmaceutical products, medical devices, and healthcare services for improved global prevention, diagnosis, and treatment of diseases of the body and mind.

Founded: 1967
Headquarters: Gyeonggi, South Korea
Website: http://www.globalgreencross.com/